Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK, safety and efficacy of doravirine/islatravir in virologically suppressed adolescents with HIV-1
2019-003597-10Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doravirine and islatravir in Human immunodeficiency virus infection type 1 (2 cohorts), sponsored by Merck & Co. Primary endpoint: ISL AUC0-24 at steady state. Started Oct 2020; status: completed.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-003597-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003597-10.